| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2010: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2009: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2008: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Research Abstract |
Osteonecrosis of the jawbone (ONJ) and its ensuing exposure induced by nitrogen-containing bisphosphonates (NBP) are taking much attention. Its underlying mechanism is not clear and there are no active methods for its prevention and treatment. Based on our findings in basic, animal experiments, we tried substitution of NBPs to etidronate (a non-NBP) for ONJ-patients with osteoporosis or tumor bone-metastasis, and observed a rapid removal of sequestra and a tendency of promoted curing. Etidronate, as a substitution drug for NBP, may be effective at treating or preventing NBP-induced ONJ or myelitis.
|
